The PHARMO Institute, part of Lumanity, delivers research insights into Neuromyelitis Optica Spectrum Disorder (NMOSD), and the PHARMO Data Network offers great research potential for this population:

    • ~180 patients identified between 2013-2023 within the hospital database

    • Data coverage across all NMOSD research centers and ~80% of multiple sclerosis centers of excellence in the Netherlands

    • Real world data (RWD) is available to address a wide range of use cases from treatment patterns, disease progression and long-term safety studies

Download our one-pager

Complete the form to download our one-pager on Real World Evidence Expertise in Neuromyelitis Optica Spectrum Disorder (NMOSD)

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.
This field is for validation purposes and should be left unchanged.